MUNDELEIN, Ill. -- (BUSINESS WIRE) -- Diabetic foot complications are the largest nontraumatic cause of lower extremity amputations, accounting for nearly 90,000 amputations a year, at a cost of nearly $40,000 per amputation procedure. To help the healing process in the most chronic wounds, including those at risk of amputations, Medline Industries, Inc., recently introduced Revitalon™, a biologic wound covering made of human amniotic tissue. Revitalon is available in an innovative multi-dot application – five, one-centimeter dots per package – which is significantly less expensive than purchasing a larger sheet.
“The Revitalon multi-dot application for chronic wounds is similar to seeding a lawn,” said Sissi Miao, Ph.D, MBA, vice president of the advanced wound care division at Medline. “The dot application allows for more efficient use of the amniotic tissue. As a result, the cost of treatment is significantly less, which is great news for the patient, as well as for the healthcare facility that is looking to control costs, provide quality care and improve outcomes.”
Revitalon is also available in sheets measuring 2x2 (centimeters), 4x4 and 6x4.
The tissue used for Revitalon amniotic membrane allografts is procured and processed by the Musculoskeletal Transplant Foundation (MTF), the country’s leading tissue bank. MTF uses the most advanced aseptic processing technique that involves maintaining Revitalon’s safety throughout the entire harvesting, processing and transporting process. This process uses fewer steps than other sterilization technologies, which creates manufacturing efficiencies that enables Revitalon to be offered at a lower cost per treatment than similar biologics.
"Amniotic membrane allografts are an outstanding weapon in our battle against the chronic wound. Because it is a natural human product, it is resistant to the body’s rejection responses,” said Matthew G. Garoufalis, DPM, FASPS, FACFAOM, CWS, Clinical Associate Professor of Podiatric Medicine and Surgery, Western University of Health Sciences, Pomona, Calif. “They can be used as an off-the-shelf product in a variety of sizes. This product plays a major and much needed role in closing the wound quickly, efficiently and cost effectively while returning the patient to his or her normal activities."
Medline partnered with Liventa Bioscience on the development of Revitalon. Liventa is the leading innovator in the use of living donor birth tissues to advance healing in wound care and orthopedic, spinal, reproductive and general surgery.
Revitalon is the newest addition to Medline’s broad array of advanced wound care programs and educational support, which along with Medline’s team of clinical consultants and product experts, provide comprehensive solutions for hard-to-heal wounds. For more information, visit http://www.medline.com/products/wound-and-skin-care/revitalon#.
As the nation's largest privately held manufacturer and distributor of health care products, Medline manufactures and distributes more than 350,000 products to hospitals, extended care facilities, surgery centers, physician offices, home care agencies and providers, and retailers. Recently named the best place to work in the medical supplies industry by sales representatives, Medline is headquartered in Mundelein, Ill., and has more than 1,100 dedicated sales representatives to support its broad product line and cost management services. For more information, go to www.medline.com and http://mkt.medline.com/clinical-blog/category/channels/social-channels/ to connect with Medline on a variety of social media channels.
About Liventa Bioscience
Liventa, headquartered in Wayne, Pa., is the leading innovator in the use of living donor birth tissues to advance healing in wound care and orthopedic, spinal, reproductive, and general surgery. Liventa’s living donor tissue forms are naturally superior coverings for difficult-to-heal wounds and for critical surgery anatomy. Liventa Bioscience, a privately held company, provides its advanced biologic coverings to physicians and hospitals throughout the United States. Click here for more information on Liventa Bioscience or visit http://www.liventabioscience.com/.